drugset
drugset / Trial / NCT03224325

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

NCT03224325 ↗

Phase 1 Completed 50 enrolled Neurocrine Biosciences Takeda · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of TAK-831 when administered as multiple oral doses at escalating dose levels in healthy participants.

Timeline

Start
2017-07-21
Primary completion
2018-09-09
Completion
2018-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Luvadaxistat Small molecule 15 mg Oral
Subject Luvadaxistat Small molecule 100 mg Oral
Subject Luvadaxistat Small molecule 300 mg Oral
Subject Luvadaxistat Small molecule 600 mg Oral
Subject Luvadaxistat Small molecule 800 mg Oral
Subject Luvadaxistat Small molecule 1200 mg Oral

Indications

No indication recorded.